Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In the Phase 2 trial, participants on retatrutide showed significant reductions in hepatic fat content, with some achieving near-complete resolution of metabolic associated steatotic liver disease
2020;318(2):F443F454
The North America obesity GLP-1 market size is estimated at USD 4.93 billion in 2025 and is projected to reach approximately USD 40.27 billion by 2035, with a 23.37% CAGR from 2026 to 2035
Correlation between Insulin Resistance and Thyroid Nodule in Type 2 Diabetes Mellitus
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
The Company assumes no obligation to update or revise these statements, except as required by law.
US$ 26.75
US$ 21.39
US$ 27.76
